Managed care initiatives along with an aging population demographics is propelling growth of the home health care, and fuelling adoption of self-administered drug therapies. Inhaled medicine is therefore increasingly being discerned as patient-friendly. The inhaled therapy in general, and dry powder inhalers in particular are deemed to be well-positioned for capitalizing on these trends, and evolving as major drivers for future development of the pharmaceutical sector, and commercialization of therapeutic drugs related to respiratory disorders.
Single-use Dry Powder Inhalers gaining Immense Traction owing to their Convenience and Easy Handling
There is a growing prevalence of chronic obstructive pulmonary disorders and asthma across the globe, particularly in developing nations, on the back of growing pollution levels and nicotine consumption. As these nations are cost-sensitive when it comes to expensive therapies regarding various respiratory diseases, demand for low-cost devices is surging across developing countries. In some places with no health insurance facilities, patients tend to share multi-use devices as the complete system become unaffordable for them. Single-use devices are therefore witnessing increased demand as they have the potential to overcome the aforementioned challenges and offer a hygienic & clean device.
A major trend being witnessed in the market is the desire for convenience and easy handling of respiratory devices. Multiple dry powder inhalers are being purchased by patients with respiratory diseases as supplementary devices for different places such as cars, job sites, and homes. With single-use dry powder inhalers, patients are enabled to carry exact dose of inhalations required in blister packs, which in turn facilitates handling and convenience.
Some essential performance characteristics of the dry powder inhalers are related to performances at varying airflows, fine particle fraction content, and dose delivery. These characteristics vary in terms of powder formulations, thereby creating the requirement for fine tuning of devices or powder formulations or both combined in order to attain optimal performance. This requirement is relatively higher in the micro-dosing dry powder inhalers. This is further expected to pave opportunities for dry powder inhaler manufacturers based on innovations and advancements.
According to a report recently published by Future Market Insights, the global dry powder inhaler market is projected to register an average expansion through the forecast period, 2017 to 2026, in terms of volume. Worldwide sales of dry powder inhales will exceed 400,000 Mn units by 2026-end.
North America to Remain Largest Market for Dry Powder Inhaler
Presence of a robust healthcare infrastructure coupled with the technologically-advanced practice, mounting number of patients with respiratory disorders, stringent guidelines by regulatory bodies regarding medical devices associated with respiratory disorder therapeutics and relatively higher healthcare spending by the government are key factors that have made North America be the most lucrative market for dry powder inhalers. Sales of dry powder inhalers in North America will exceed 160,000 Mn units by 2026-end.
Chronic obstructive pulmonary disease will continue to be the fast-expanding application of dry powder inhalers. However, dry powder inhaler sales for application in asthma will remain relatively larger than those in chronic obstructive pulmonary disease.
Key Research Findings from FMI’s Report
- Multi-dose dry powder inhaler will continue to be dominant among products in the market
- Hospital pharmacies will remain the fastest expanding distribution channel for dry powder inhalers
Get a free sample request @ https://www.xploremr.com/connectus/sample/397
Leading players in the global market for dry powder inhalers are concentrating on developing new generation products. These market players are investing in R&D activities apropos to novel device architectures, powder formulations, and particle engineering. Development of enhanced particle properties, and efficient inhaler designs are expected to remain major strategies among the market participants.
The report profiles key market participants, which include Astrazeneca Plc., 3M Company, GlaxoSmithKline Plc, Novartis AG, Cipla Ltd., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Chiesi Farmaceutici S.p.A., MannKind Corporation, and Vectura Group Plc.